{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:41:20Z","timestamp":1792453280207,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T00:00:00Z","timestamp":1359331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cancer of unknown primary site (CUP) is considered an aggressive metastatic disease but whether the prognosis differs from metastatic cancers of known primary site is not known. Such data may give insight into the biology of CUP and the metastatic process in general.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>6,745 cancer patients, with primary metastatic cancer at diagnosis, were identified from the Swedish Cancer Registry, and were compared with 2,881 patients with CUP. Patients were diagnosed and died between 2002 and 2008. The influence of the primary site, known or unknown, on survival in patients with metastases at specific locations was investigated. Hazard ratios (HRs) of death were estimated for several sites of metastasis, where patients with known primary sites were compared with CUP patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, patients with metastatic cancers with known primary sites had decreased hazards of death compared to CUP patients (HR\u2009=\u20090.69 [95% CI\u2009=\u20090.66\u20130.72]). The exceptions were cancer of the pancreas (1.71 [1.54\u20131.90]), liver (1.58 [1.36\u20131.85]), and stomach (1.16 [1.02\u20131.31]). For individual metastatic sites, patients with liver or bone metastases of known origin had better survival than those with CUP of the liver and bone. Patients with liver metastases of pancreatic origin had an increased risk of death compared with patients with CUP of the liver (1.25 [1.06\u20131.46]). The median survival time of CUP patients was three months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with CUP have poorer survival than patients with known primaries, except those with brain and respiratory system metastases. Of CUP sites, liver metastases had the worst prognosis. Survival in CUP was comparable to that in metastatic lung cancer. The aggressive behavior of CUP may be due to initial immunosuppression and immunoediting which may allow accumulation of mutations. Upon escape from the suppressed state an unstoppable tumor spread ensues. These novel data on the epidemiology of the metastatic process at the population level demonstrated large survival differences in organ defined metastases depending on the original cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2407-13-36","type":"journal-article","created":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T15:14:21Z","timestamp":1359386061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Matias","family":"Riihim\u00e4ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,28]]},"reference":[{"issue":"11","key":"3642_CR1","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/ijc.26031","volume":"128","author":"RR Langley","year":"2011","unstructured":"Langley RR, Fidler IJ: The seed and soil hypothesis revisited\u2013the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011, 128 (11): 2527-2535. 10.1002\/ijc.26031.","journal-title":"Int J Cancer"},{"issue":"11","key":"3642_CR2","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/ijc.26027","volume":"128","author":"JP Sleeman","year":"2011","unstructured":"Sleeman JP, Nazarenko I, Thiele W: Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011, 128 (11): 2511-2526. 10.1002\/ijc.26027.","journal-title":"Int J Cancer"},{"issue":"8","key":"3642_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm1469","volume":"12","author":"PS Steeg","year":"2006","unstructured":"Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006, 12 (8): 895-904. 10.1038\/nm1469.","journal-title":"Nat Med"},{"issue":"4","key":"3642_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc2627","volume":"9","author":"CA Klein","year":"2009","unstructured":"Klein CA: Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009, 9 (4): 302-312. 10.1038\/nrc2627.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3642_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc2772","volume":"10","author":"M Collado","year":"2010","unstructured":"Collado M, Serrano M: Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010, 10 (1): 51-57. 10.1038\/nrc2772.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3642_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2101","volume":"8","author":"DX Nguyen","year":"2007","unstructured":"Nguyen DX, Massague J: Genetic determinants of cancer metastasis. Nat Rev Genet. 2007, 8 (5): 341-352.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"3642_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/sj.bjc.6605214","volume":"101","author":"LL Chen","year":"2009","unstructured":"Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS: Cancer metastasis networks and the prediction of progression patterns. Br J Cancer. 2009, 101 (5): 749-758. 10.1038\/sj.bjc.6605214.","journal-title":"Br J Cancer"},{"issue":"11","key":"3642_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/sj.bjc.6605373","volume":"101","author":"KE Smedby","year":"2009","unstructured":"Smedby KE, Brandt L, Backlund ML, Blomqvist P: Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer. 2009, 101 (11): 1919-1924. 10.1038\/sj.bjc.6605373.","journal-title":"Br J Cancer"},{"issue":"6","key":"3642_CR9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","volume":"132","author":"G Disibio","year":"2008","unstructured":"Disibio G, French SW: Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008, 132 (6): 931-939.","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"3642_CR10","first-page":"3403","volume":"5","author":"KR Hess","year":"1999","unstructured":"Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999, 5 (11): 3403-3410.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3642_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer. 2006, 106 (7): 1624-1633. 10.1002\/cncr.21778.","journal-title":"Cancer"},{"issue":"3","key":"3642_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ije\/29.3.495","volume":"29","author":"LA Johansson","year":"2000","unstructured":"Johansson LA, Westerling R: Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000, 29 (3): 495-502. 10.1093\/ije\/29.3.495.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"3642_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/0269216308092285","volume":"22","author":"J Cohen","year":"2008","unstructured":"Cohen J, Bilsen J, Addington-Hall J, Lofmark R, Miccinesi G, Kaasa S, Onwuteaka-Philipsen B, Deliens L: Population-based study of dying in hospital in six European countries. Palliat Med. 2008, 22 (6): 702-710. 10.1177\/0269216308092285.","journal-title":"Palliat Med"},{"key":"3642_CR14","unstructured":"D\u00f6dsorsaker 2010 (Causes of death 2010): The Swedish national board of health and welfare. Accessible online at http:\/\/www.socialstyrelsen.se\/publikationer2011\/2011-7-6"},{"issue":"2","key":"3642_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/annonc\/mdg068","volume":"14","author":"AJ van de Wouw","year":"2003","unstructured":"van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF: The unknown biology of the unknown primary tumour: a literature review. Ann Oncol. 2003, 14 (2): 191-196. 10.1093\/annonc\/mdg068.","journal-title":"Ann Oncol"},{"issue":"3","key":"3642_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1025621819250","volume":"64","author":"S Bartelt","year":"2003","unstructured":"Bartelt S, Lutterbach J: Brain metastases in patients with cancer of unknown primary. J Neurooncol. 2003, 64 (3): 249-253. 10.1023\/A:1025621819250.","journal-title":"J Neurooncol"},{"issue":"10","key":"3642_CR17","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/ijc.24795","volume":"126","author":"K Hemminki","year":"2010","unstructured":"Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J: The Swedish family-cancer database 2009: prospects for histology-specific and immigrant studies. Int J Cancer. 2010, 126 (10): 2259-2267.","journal-title":"Int J Cancer"},{"key":"3642_CR18","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1093\/annonc\/mds063","volume":"23","author":"K Hemminki","year":"2012","unstructured":"Hemminki K, Bevier M, Sundquist J, Hemminki A: Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?. Ann Oncol. 2012, 23: 2720-2724. 10.1093\/annonc\/mds063.","journal-title":"Ann Oncol"},{"issue":"8","key":"3642_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ctrv.2008.05.005","volume":"34","author":"G Lazaridis","year":"2008","unstructured":"Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N: Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008, 34 (8): 693-700. 10.1016\/j.ctrv.2008.05.005.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3642_CR20","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/cncr.21454","volume":"104","author":"V Karavasilis","year":"2005","unstructured":"Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005, 104 (10): 2282-2287. 10.1002\/cncr.21454.","journal-title":"Cancer"},{"issue":"1","key":"3642_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2407-5-25","volume":"5","author":"V Karavasilis","year":"2005","unstructured":"Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer. 2005, 5 (1): 25-10.1186\/1471-2407-5-25.","journal-title":"BMC Cancer"},{"issue":"7","key":"3642_CR22","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","volume":"23","author":"K Hemminki","year":"2012","unstructured":"Hemminki K, Bevier M, Hemminki A, Sundquist J: Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012, 23 (7): 1854-1863. 10.1093\/annonc\/mdr536.","journal-title":"Ann Oncol"},{"key":"3642_CR23","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G: Cancer of unknown primary site. Lancet. 2012, 379: 1428-1435. 10.1016\/S0140-6736(11)61178-1.","journal-title":"Lancet"},{"key":"3642_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/02841860902862503","volume":"48","author":"M Randen","year":"2009","unstructured":"Randen M, Rutqvist LE, Johansson H: Cancer patients without a known primary: incidence and survival trends in Sweden 1960\u20132007. Acta Oncol. 2009, 48: 915-920. 10.1080\/02841860902862503.","journal-title":"Acta Oncol"},{"key":"3642_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/CEJ.0b013e32834c9ceb","volume":"21","author":"X Shu","year":"2012","unstructured":"Shu X, Sundquist K, Sundquist J, Hemminki K: Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev. 2012, 21: 281-288. 10.1097\/CEJ.0b013e32834c9ceb.","journal-title":"Eur J Cancer Prev"},{"issue":"Suppl 6","key":"3642_CR26","doi-asserted-by":"crossref","first-page":"vi64","DOI":"10.1093\/annonc\/mdr389","volume":"22","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G: Cancer of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22 (Suppl 6): vi64-vi68.","journal-title":"Ann Oncol"},{"key":"3642_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/annonc\/mdr306","volume":"23","author":"FA Greco","year":"2012","unstructured":"Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H: Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2012, 23: 298-304. 10.1093\/annonc\/mdr306.","journal-title":"Ann Oncol"},{"issue":"4","key":"3642_CR28","first-page":"297","volume":"15","author":"S Mylona","year":"2009","unstructured":"Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L: Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn Interv Radiol. 2009, 15 (4): 297-302.","journal-title":"Diagn Interv Radiol"},{"issue":"14","key":"3642_CR29","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ejca.2006.04.012","volume":"42","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006, 42 (14): 2212-2221. 10.1016\/j.ejca.2006.04.012.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3642_CR30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/bjs.7032","volume":"97","author":"EJ Morris","year":"2010","unstructured":"Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G: Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010, 97 (7): 1110-1118. 10.1002\/bjs.7032.","journal-title":"Br J Surg"},{"issue":"2","key":"3642_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.gie.2009.08.025","volume":"71","author":"J DeWitt","year":"2010","unstructured":"DeWitt J, Yu M, Al-Haddad MA, Sherman S, McHenry L, LeBlanc JK: Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointest Endosc. 2010, 71 (2): 260-265. 10.1016\/j.gie.2009.08.025.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"3642_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1245\/s10434-006-9131-8","volume":"14","author":"SV Shrikhande","year":"2007","unstructured":"Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Buchler MW: Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007, 14 (1): 118-127.","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"3642_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364 (19): 1817-1825. 10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"20 Pt 2","key":"3642_CR34","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006, 12 (20 Pt 2): 6243s-6249s.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3642_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/17453674.2011.552779","volume":"82","author":"RJ Weiss","year":"2011","unstructured":"Weiss RJ, Wedin R: Surgery for skeletal metastases in lung cancer. Acta Orthop. 2011, 82 (1): 96-101. 10.3109\/17453674.2011.552779.","journal-title":"Acta Orthop"},{"issue":"7","key":"3642_CR36","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.intimp.2010.12.024","volume":"11","author":"T Chan","year":"2011","unstructured":"Chan T, Wiltrout RH, Weiss JM: Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol. 2011, 11 (7): 879-889. 10.1016\/j.intimp.2010.12.024.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"3642_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002, 3 (11): 991-998. 10.1038\/ni1102-991.","journal-title":"Nat Immunol"},{"issue":"Suppl 5","key":"3642_CR38","doi-asserted-by":"publisher","first-page":"v228","DOI":"10.1093\/annonc\/mdq193","volume":"21","author":"N Pavlidis","year":"2010","unstructured":"Pavlidis N, Briasoulis E, Pentheroudakis G: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21 (Suppl 5): v228-v231.","journal-title":"Ann Oncol"},{"issue":"10","key":"3642_CR39","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/sj.bjc.6601785","volume":"90","author":"A Piga","year":"2004","unstructured":"Piga A, Nortilli R, Cetto GL, Cardarelli N, Fedeli SL, Fiorentini G, D\u2019Aprile M, Giorgi F, Parziale AP, Contu A, et al: Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer. 2004, 90 (10): 1898-1904. 10.1038\/sj.bjc.6601785.","journal-title":"Br J Cancer"},{"issue":"3","key":"3642_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0959-8049(01)00378-1","volume":"38","author":"AJ van de Wouw","year":"2002","unstructured":"van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984\u20131992. Eur J Cancer. 2002, 38 (3): 409-413. 10.1016\/S0959-8049(01)00378-1.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-36\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T07:18:27Z","timestamp":1714893507000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3642"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-36","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,28]]},"assertion":[{"value":"8 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"36"}}